VVOS vs. PSTV, GBS, NURO, AVGR, TMDIF, GMVDF, VERO, UTRS, AFIB, and STSS
Should you be buying Vivos Therapeutics stock or one of its competitors? The main competitors of Vivos Therapeutics include Plus Therapeutics (PSTV), GBS (GBS), NeuroMetrix (NURO), Avinger (AVGR), Titan Medical (TMDIF), G Medical Innovations (GMVDF), Venus Concept (VERO), Minerva Surgical (UTRS), Acutus Medical (AFIB), and Sharps Technology (STSS). These companies are all part of the "surgical & medical instruments" industry.
Plus Therapeutics (NASDAQ:PSTV) and Vivos Therapeutics (NASDAQ:VVOS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, media sentiment, community ranking, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations.
Vivos Therapeutics has a net margin of -98.42% compared to Vivos Therapeutics' net margin of -271.04%. Plus Therapeutics' return on equity of -665.17% beat Vivos Therapeutics' return on equity.
In the previous week, Plus Therapeutics had 4 more articles in the media than Vivos Therapeutics. MarketBeat recorded 4 mentions for Plus Therapeutics and 0 mentions for Vivos Therapeutics. Vivos Therapeutics' average media sentiment score of 0.41 beat Plus Therapeutics' score of 0.00 indicating that Plus Therapeutics is being referred to more favorably in the media.
Plus Therapeutics presently has a consensus price target of $10.00, indicating a potential upside of 502.41%. Given Vivos Therapeutics' higher probable upside, research analysts plainly believe Plus Therapeutics is more favorable than Vivos Therapeutics.
Plus Therapeutics received 51 more outperform votes than Vivos Therapeutics when rated by MarketBeat users. Likewise, 60.58% of users gave Plus Therapeutics an outperform vote while only 52.17% of users gave Vivos Therapeutics an outperform vote.
Plus Therapeutics has higher earnings, but lower revenue than Vivos Therapeutics. Vivos Therapeutics is trading at a lower price-to-earnings ratio than Plus Therapeutics, indicating that it is currently the more affordable of the two stocks.
3.3% of Plus Therapeutics shares are owned by institutional investors. Comparatively, 26.4% of Vivos Therapeutics shares are owned by institutional investors. 2.3% of Plus Therapeutics shares are owned by company insiders. Comparatively, 9.6% of Vivos Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Plus Therapeutics has a beta of 0.59, meaning that its stock price is 41% less volatile than the S&P 500. Comparatively, Vivos Therapeutics has a beta of 7.95, meaning that its stock price is 695% more volatile than the S&P 500.
Summary
Plus Therapeutics beats Vivos Therapeutics on 10 of the 17 factors compared between the two stocks.
Get Vivos Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VVOS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VVOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vivos Therapeutics Competitors List
Related Companies and Tools
